Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Open access
Wagner, Michael J, Othus, Megan, Patel, Sandip P, Ryan, Chris, Sangal, Ashish, Powers, Benjamin, Budd, G Thomas, Victor, Adrienne I, Hsueh, Chung-Tsen, Chugh, Rashmi, Nair, Suresh, Leu, Kirsten M, Agulnik, Mark, Sharon, Elad, Mayerson, Edward, Plets, Melissa, Blanke, Charles, Streicher, Howard, Chae, Young Kwang, Kurzrock, Razelle · 2021 · Journal for ImmunoTherapy of Cancer

Abstract

Purpose: Angiosarcoma is a rare aggressive endothelial cell cancer with high mortality. Isolated reports suggest immune checkpoint inhibition efficacy in angiosarcoma, but no prospective studies have been published. We report results for angiosarcoma treated with ipilimumab and nivolumab as a cohort of an ongoing rare cancer study. Methods: This is a prospective, open-label, multicenter phase II clinical trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks) for metastatic or unresectable angiosarcoma. Primary endpoint was objective response rate (ORR) per RECIST 1.1. Secondary endpoints include progression-free (PFS) and overall survival, and toxicity. A two-stage design was used. Results: Overall, there were 16 evaluable patients. Median age was 68 years (range, 25–81); median number of prior lines of therapy, 2. Nine patients had cutaneous and seven non-cutaneous primary tumors. ORR was 25% (4/16). Sixty per cent of patients (3/5) with primary cutaneous scalp or face tumors attained a confirmed response. Six-month PFS was 38%. Altogether, 75% of patients experienced an adverse event (AE) (at least possibly related to drug) (25% grade 3–4 AE); 68.8%, an immune-related AE (irAE) (2 (12.5%), grade 3 or 4 irAEs (alanine aminotransferase/aspartate aminotransferase increase and diarrhea)). There were no grade 5 toxicities. One of seven patients in whom tumor mutation burden (TMB) was assessed showed a high TMB (24 mutations/mb); that patient achieved a partial response (PR). Two of three patients with PDL1 immunohistochemistry assessed had high PDL1 expression; one achieved a PR. Conclusion: The combination of ipilimumab and nivolumab demonstrated an ORR of 25% in angiosarcoma, with three of five patients with cutaneous tumors of the scalp or face responding. Ipilimumab and nivolumab warrant further investigation in angiosarcoma. Trial registration number: NCT02834013.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2021-002990

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 169

Metadata

Authors
Wagner, M. J., Othus, M., Patel, S. P., Ryan, C., Sangal, A., Powers, B., Budd, G. T., Victor, A. I., Hsueh, C.-T., Chugh, R., Nair, S., Leu, K. M., Agulnik, M., Sharon, E., Mayerson, E., Plets, M., Blanke, C., Streicher, H., Chae, Y. K., & Kurzrock, R.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2021-08
Volume
9
Issue
8
Pages
e002990
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3099993684
Cited by
169
References
6
FWCI
8.23
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). https://app.cochat.ai/papers/10.1136/jitc-2021-002990
The paper
Wagner, M. J., Othus, M., Patel, S. P., Ryan, C., Sangal, A., Powers, B., Budd, G. T., Victor, A. I., Hsueh, C.-T., Chugh, R., Nair, S., Leu, K. M., Agulnik, M., Sharon, E., Mayerson, E., Plets, M., Blanke, C., Streicher, H., Chae, Y. K., & Kurzrock, R. (2021). Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-002990

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.